# EDGAR Filing Document

**Accession Number:** 0001810560
**File Stem:** 0000950170-23-000613
**Filing Date:** 2023-1
**Character Count:** 26963
**Document Hash:** c6117d20e30a431e66d76364958d675f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-000613.hdr.sgml**: 20230110

**ACCESSION NUMBER**: 0000950170-23-000613

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 42

**CONFORMED PERIOD OF REPORT**: 20230109

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230110

**DATE AS OF CHANGE**: 20230110

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REVELATION BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001810560
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 843898466
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39603
- **FILM NUMBER:** 23521210

**BUSINESS ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122
- **BUSINESS PHONE:** 650-800-3717

**MAIL ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Petra Acquisition Inc.
- **DATE OF NAME CHANGE:** 20200423

?xml version="1.0" encoding="ASCII"? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** January 09, 2023<br>

------

REVELATION BIOSCIENCES, INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-39603 | 84-3898466 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 4660 La Jolla Village Drive<br>Suite 100 |  |  |
| San Diego**,** California |  | 92122 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (650) 800-3717<br>

Not Applicable

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Units, each consisting of one share of common stock and one redeemable warrant | REVBU | The NASDAQ Stock Market LLC |
| Common stock, par value $0.001 per share | REVB | The NASDAQ Stock Market LLC |
| Redeemable warrants, each exercisable for a share of common stock at an exercise price of $11.50 per share | REVBW | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01 Regulation FD Disclosure.** 

On January 9, 2023, Revelation Biosciences, Inc. made an updated corporate presentation available to the public. A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information in Item 7.01 and in Exhibit 99.1 will not be treated as "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits.

[<u>99.1</u>](revb-ex99_1.htm) [<u>Corporate Presentation dated January 9, 2023</u>](revb-ex99_1.htm) <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **REVELATION BIOSCIENCES, INC.** |
| Date: | January 10, 2023 | By:  | /s/ Chester S. Zygmont, III |
|  |  |  | **Chester S. Zygmont, III**<br> Chief Financial Officer<br>(principal financial and accounting officer) |

---

------

## Exhibit 99.1

![Slide 1](revb-ex99_1s1.jpg)

Developing innovative therapeutics to address unmet needs Corporate Presentation / January 2023 www.revbiosciences.com

------

![Slide 2](revb-ex99_1s2.jpg)

Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions investors not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the clinical utility of an increase in intranasal cytokine levels as a biomarker of viral infections; the risk that our preclinical studies will not demonstrate sufficient positive data to support commencement of clinical trials; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for REVTx-100, REVTx-200, REVTx-300, REVTx-99b, REVDx-501, or any other product candidates; potential indications for which product candidates may be developed; the potential impact that COVID 19 may have on Revelation's suppliers, vendors, regulatory agencies, employees and the global economy as a whole; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; the ability of Revelation to obtain further financing and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

------

![Slide 3](revb-ex99_1s3.jpg)

Therapeutic Development Pipeline Revelation has developed a robust pipeline of potential high-value products based on the activity of PHAD All current product candidates are based on PHAD. REVTx-100 and REVTx-300 are supported by preclinical data Therapeutic Candidate Discovery Preclinical Phase 1 Phase 2 Next Milestone REVTx-100 Initiate Phase 1a\* study REVTx-300 Initiate Phase 1a\* study REVTx-200 Readout from PEITHO nonclinical study REVTx-99b Initiate non-clinical study Acute/chronic kidney disease Adjunct to IM vaccine Food allergies Prevention of post surgical infection \*Phase 1a is the same study, data will be used for REVTx-100 and REVTx-300

------

![Slide 4](revb-ex99_1s4.jpg)

Cytokine induction PHAD is a Well-Defined TLR4 Agonist with Multiple Potential Applications Treatment of acute and chronic inflammatory disease such as AKI, CKD and NASH (REVTx-300) PHAD Modulation of Immune Response Prevention and treatment of healthcare associated infection via trained immunity ((REVTx-100 (licensed from Vanderbilt University)) Recruit immune cells to the mucosa to augment the local and systemic adaptive immune response (REVTx-200) Treatment of food allergies and allergic rhinitis (REVTx-99b) IL-6 TNF-a IP-10 MCP-1 Revelation has developed proprietary formulations and methods of use to deliver phosphorylated hexaacyl disaccharide (PHAD®) systemically or to the local intranasal cavity to treat various diseases

------

![Slide 5](revb-ex99_1s5.jpg)

REVTx-100 For the Prevention of Healthcare Associated Infection

------

![Slide 6](revb-ex99_1s6.jpg)

REVTx-100 Program Highlights Scientific Rationale 1. 2015 HAI and Antibiotic Use Prevalence Survey, CDC.gov Stimulation of the TLR4 TRIF pathway with REVTx-100: Augments immune cell recruitment, which increases pathogen clearance Downregulates the pro-inflammatory response allowing healing to take place Multiple preclinical studies performed demonstrating consistent reduction or prevention of infection (both gram negative and gram positive) IV Administration of REVTx100 Intellectual Property US 11,389,465 (Licensed from Vanderbilt University). Additional related applications anticipated Regulatory Potential fast track, breakthrough designations possible. Potential for orphan status for certain indications Market Large Market potential: Approximately 3% of hospital patients suffer at least one hospital associated infection (HAI) (~687,000 HAI annual cases in acute care settings resulting in ~72,000 deaths)1 Next Steps Initiate Phase 1 healthy volunteer study in 2023

------

![Slide 7](revb-ex99_1s7.jpg)

Pretreatment with PHADs Impart Protection from Gram Negative Bacterial Infection Hernandez, et. al. Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens. DOI: 10.1097/CCM.0000000000003967 Study Design: Mice were pre-treated (24 and 48 hours) with vehicle, MPLA (20ug), or PHADs (20ug) prior to infection with P. aeruginosa. All given IP. Cell counts assessed from peritoneal lavage 6 hours post infection. n = 7 to 10 animals per group. Pre-treatment with MPLA and PHAD(s) demonstrated TLR4-mediated pathogen clearance Pre-treatment with MPLA or PHAD(s) demonstrated TLR4-mediated increased leukocyte recruitment and reduced pro-inflammatory cytokines (IL-6, TNF-a) in peritoneal cavity

------

![Slide 8](revb-ex99_1s8.jpg)

Study Design: Mice were pre-treated (24 and 48 hours) with vehicle, MPLA (1 mg/kg), or PHADs (1 mg/kg) prior to infection with S. aureus. All given IV. Bacterial counts assessed 3 days post infection. n = 7 to 10 animals per group. Pre-treatment with MPLA and PHAD(s) demonstrated improved pathogen clearance 3 days post infection Pre-treatment with MPLA and PHAD(s) demonstrated improved survival Hernandez, et. al. Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens. DOI: 10.1097/CCM.0000000000003967 Pretreatment with PHADs Impart Protection from Gram Positive Bacterial Infection

------

![Slide 9](revb-ex99_1s9.jpg)

Study Design: Mice were pre-treated (24 and 48 hours) with vehicle, MPLA (1 mg/kg), or PHADs (1 mg/kg) prior to infection with S. aureus. All given IV. Bacterial counts assessed 3 days post infection. n = 7 to 10 animals per group. Biomarkers (cytokines) support the underlying mechanism of PHAD Significant reduction in pro-inflammatory cytokines indicates TRIF-biased signaling via TLR4 stimulation Hernandez, et. al. Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens. DOI: 10.1097/CCM.0000000000003967

------

![Slide 10](revb-ex99_1s10.jpg)

The Impact of Surgical-Site Infections (SSI) DOI:10.1001/jamasurg DOI:10.1086/676022 DOI: 10.1016/j.jamcollsurg.2016.10.029 ~€11bn represents the midpoint of the range discussed in WHO Global guidelines on the prevention of surgical site infection. Nov 2016 DOI: 10.1086/501572 Up to 30% Estimated SSI rate of patients undergoing colorectal surgery1 20% SSI rate of all health care-associated infections in US hospitals2 $11k-26k Cost of treatment per infection directly attributable to SSIs 7-11 days Additional post-operative hospital days for patients with SSIs2 2-11x Increased risk of death for SSI patient (up to 40% mortality after deep sternal infection)1 US $10bn; EU~€11bn Estimated SSI-related incrementalannual hospital costs in the US and EU3,4,5 Surgical site infection (SSI) is the most common health care-associated infection following surgery and is associated with significant morbidity and mortality, transfer to an intensive care unit setting, prolonged hospitalizations, and hospital readmission6

------

![Slide 11](revb-ex99_1s11.jpg)

Total US Addressable Market for REVTx-100 is over 6.3M Annual Procedures Operations on the digestive system 3.8M Operations on the urinary system 567K Operations on the male genital system 360K Operations on the female genital system 1.6M Surgeries in Hospital-Based Ambulatory Surgery and Hospital Inpatient Settings, 2014 Claudia A. Steiner, M.D., M.P.H., Zeynal Karaca, Ph.D., Brian J. Moore, Ph.D., Melina C. Imshaug, M.P.H., and Gary Pickens, Ph.D.

------

![Slide 12](revb-ex99_1s12.jpg)

REVTx-100 Development Plan REVTx-100 has potential utility across multiple indications Revelation plans to develop REVTx-100 as a treatment for multiple indications through Phase 2 Plan to strategic license and/or partner for Phase 3 studies and commercialization Phase Target Indication1 Anticipated Timing Use of Data Preclinical Tox 2023 Support US IND Phase 1a Healthy volunteers 2023 Support Phase 1b study for REVTx-100 and REVTx-300 Phase 1b Post-surgical infection (abdominal) 2024 Support Phase 2 study Phase 2 Post-surgical infection (abdominal) 2024/2025 Support Phase 3 study/Partnering discussion Phase 2 Pneumonia (post sepsis) 2025 Phase 2 Post burn2 TBD Phase 2 UTI TBD Potential for fast track and breakthrough designation Potential for orphan status

------

![Slide 13](revb-ex99_1s13.jpg)

REVTx-100 Phase 1a/1b Draft Clinical Study Design 6 cohorts/8 subjects per cohort randomized 1:1 placebo vs drug: Phase 1a: Healthy volunteers1 Phase 1b: Patients undergoing elective abdominal colorectal surgery 30 subjects randomized 1:1:1 placebo: low dose group: high dose group Cohorts 1-5 - single ascending dose followed for 1 week Cohort 6 – 5 daily doses at maximum tolerated dose followed for 1 week post last dose Readouts: safety and biomarker assessments Readouts: safety and biomarker assessments All doses 24 hours prior to surgery. Follow for 4 weeks Readout: safety and biomarker assessments, including infection rate, duration, and severity. 1. Only one Phase 1a study needed for both REVTx-100 and REVTx-300

------

![Slide 14](revb-ex99_1s14.jpg)

REVTx-300 For the Treatment of Acute and Chronic Kidney Diseases

------

![Slide 15](revb-ex99_1s15.jpg)

REVTx-300 Program Highlights 1. Zwirner, N. and Ziblat, A. 2017 doi: 10.3389/fimmu.2017.00025 2. Ismaeli, J. et. al. 2022 doi: 10.4049/jimmunol.168.2.926 3. Hernandez, A. et. al. 2019 DOI: 10.1097/CCM.0000000000003967 Chronic and acute organ disease (AKI, CKD, NASH, and myocarditis) propagated by inflammation, followed by fibrosis, and ultimately loss of organ function Significant anti-fibrotic activity observed in preclinical AKI and CKD model with PHAD treatment Scientific Rationale Intellectual Property Developed at/by Revelation. Patent applications covering formulations and methods of treating and preventing acute and chronic organ disease filed Market CDC estimated 15% of US adults have CKD CDC estimates an annual Medicare cost for CKD of $87 billion Next steps Conduct additional nonclinical studies for AKI, CKD, NASH, and myocarditis. Initiate Phase 1a study in 2023 (This is the same Phase 1a study as for REVTx-100, data will support both) 1, 2, 3 1, 2, 3 \*1,2,3

------

![Slide 16](revb-ex99_1s16.jpg)

REVTx-300 Reduces Fibrosis in Acute and Chronic Kidney Model (UUO in Rats) Composite data represents the average of 3 anatomically distinct depths (10 images / depth / rat / group = ~60-65% of renal cortical area) Renal cortical fibrosis, expressed as Collagen Volume Fraction (CVF; via quantitation of PSR stained tissue sections) was increased in vehicle-treated UUO obstructed kidneys relative to sham-operated control SB-525334 attenuated UUO-induced increases in renal cortical CVF Key Results Treatment with REVTx-300 resulted in a significant dose-dependent reduction in fibrosis The high dose group (0.9 mg/kg) reduced new collagen deposition (fibrosis) by 58% vs new collagen deposition observed in the no treatment UUO group (normalized to sham)

------

![Slide 17](revb-ex99_1s17.jpg)

REVTx-300 Antifibrotic Effect Likely Mediated by Reduction in TGF-b Next Steps Conduct additional nonclinical studies to further evaluate REVTx-300 for AKI, CKD, and NASH Phase 1 clinical study in 2023 Normal TNF-a range = 5-75pg/mL 1,2 1. Yin, J., et. al. Changes and significance of inflammatory cytokines in a rat model of cervical spondylosis". Experimental and Therapeutic Medicine 15.1 (2018): 400-406. 2. LI, Bo, et.al. Food Science and Technology (Campinas). 2017. 37. 10.1590/1678-457x.35716.

------

![Slide 18](revb-ex99_1s18.jpg)

TGF-b has been correlated with fibrosis in multiple clinical populations, including acute kidney injury, chronic kidney disease, NASH, and myocarditis. TGF-b is also a driver of tumor growth, and increased levels have been observed in cancer patients.1,2,3,4 Multiple therapies targeting the reduction in TGF-b have been pursued, with mixed results: ALK5 inhibitors Effective in blocking TGF-b activity via binding to TGF-b receptor Major safety hurdles - valvulopathy and bone dysplasia in preclinical models Galunisertib furthest in development (oncology indication), discontinued in 2020, no reason provided (Eli Lilly) Anti-TGF-b MAb Multiple ongoing studies, several halted due to futility Anti-sense oligonucleotides Multiple ongoing studies, several halted Complete knock down of TGF-b likely associated with adverse events Safety profile of MPLA and observed tolerability of PHAD may afford wider therapeutic window compared to other anti-fibrotic treatments that target reduction in TGF-b Mohy doi: 10.1016/j.mgene.2014.08.002 Tian doi: 10.3892/etm.2019.8355 3. Nawar, Elham A. et al. "Clinical value of transforming growth factor beta as a marker of fibrosis in adolescents with Chronic Liver Diseases." (2011) 4. De Heer, E., et. al. Nephrol Dial Transplant (2000) 15 [Suppl 6]: 72–73 Reduction in TGF-b Has Been Shown to Be a Predictive Surrogate Clinical Biomarker and Potential Therapeutic Target for Reduction of Fibrosis and Treatment of Cancer

------

![Slide 19](revb-ex99_1s19.jpg)

AKI Epidemiology In the US, 1% of all hospital admissions have AKI on admission1 During hospitalization, the approximate incidence rate of acute kidney injury is 2 to 5% and it develops in up to 67% of patients admitted in the intensive care unit1 AKI is an important contributor to increased hospital stay duration and patient morbidity 2,3,4 1. Acute Kidney Injury Abhinav Goyal; Parnaz Daneshpajouhnejad; Muhammad F. Hashmi; Khalid Bashir 2. Winther-Jensen M, Kjaergaard J, Lassen JF, Køber L, Torp-Pedersen C, Hansen SM, Lippert F, Kragholm K, Christensen EF, Hassager C. Use of renal replacement therapy after out-of-hospital cardiac arrest in Denmark 2005-2013. Scand Cardiovasc J. 2018 Oct;52(5):238-243 3. Park S, Lee S, Lee A, Paek JH, Chin HJ, Na KY, Chae DW, Kim S. Awareness, incidence and clinical significance of acute kidney injury after non-general anesthesia: A retrospective cohort study. Medicine (Baltimore). 2018 Aug;97(35):e12014. 4. Kirkley MJ, Boohaker L, Griffin R, Soranno DE, Gien J, Askenazi D, Gist KM., Neonatal Kidney Collaborative (NKC). Acute kidney injury in neonatal encephalopathy: an evaluation of the AWAKEN database. Pediatr Nephrol. 2019 Jan;34(1):169-176. 5. CDC Trends in Hospitalizations for Acute Kidney Injury — United States, 2000–2014 6 .Acute kidney injury identified by the following International Classification of Diseases, Ninth Revision, Clinical Modification codes: at least one diagnostic code of 584 or at least one procedure code of 39.95 or 54.98 and excluding the following codes: V45.1, V56.0, V56.31, V56.32, and V56.8. Age-standardized incidence of hospitalizations with acute kidney injury6 among men and women aged ≥20 years with and without diabetes — United States, 2000–20145

------

![Slide 20](revb-ex99_1s20.jpg)

AKI as a Result of Cardiac Surgery DOI: 10.2147/IJNRD.S167477 DOI: 10.1097/ACO.0000000000000422 DOI: 10.214470/1678-9741-2018-0084 Up to 31% Of patients undergoing cardiac surgery with no prior CKD develop post operative AKI3 50% Death rate of patients that develop post operative AKI2 $42.6k Average cost of treatment directly attributable to AKI2 4-7 days Additional hospital days for patients with postoperative AKI2 8x Increased risk of death for patients that develop postoperative AKI3 79% Rate of postoperative AKI patients that develop a least one other complication2 Acute kidney injury is a major medical problem that is of particular concern after cardiac surgery.1 Additionally, evidence suggests that even slight postoperative increases in serum creatinine levels are associated with a significant increase in the risk of death.2

------

![Slide 21](revb-ex99_1s21.jpg)

AKI and CKD Markets

------

![Slide 22](revb-ex99_1s22.jpg)

REVTx-300 Development Plan Phase Indication Anticipated Timing Use of Data Preclinical AKI (I/R) 2023 Support IND Preclinical CKD 2023 Support IND Preclinical NASH 2023 Support additional indication Phase 1a Healthy volunteer 2023 Support Phase 1b study for REVTx-100 and REVTx-300 Phase 1b AKI1 2024 Support Phase 2 study Phase 2 AKI1 2024/2025 Support Phase 3 study/Partnering discussion Phase 2 CKD1 2025 Phase 2 NASH1 TBD Potential fast track, breakthrough designations possible REVTx-300 has potential utility across multiple indications Plan is to develop REVTx-300 as a treatment for multiple indications through Phase 2 Plan to strategic license and/or partner for Phase 3 studies and commercialization Tox data from REVTx-100 will also support the AKI indication below

------

![Slide 23](revb-ex99_1s23.jpg)

REVTx-300 Phase 1a/1b Draft Clinical Study Design 6 cohorts/8 subjects per cohort randomized 1:1 placebo vs drug: Phase 1a: Health volunteers1 Phase 1b: Patients undergoing elective cardiac surgery 30 subjects randomized 1:1:1 placebo: low dose group: high dose group Cohorts 1-5 - single ascending dose followed for 1 week Cohort 6 – 5 daily doses at maximum tolerated dose followed for 1 week post last dose Readouts: safety and biomarker assessments Readouts: safety and biomarker assessments All doses 24 hours prior to surgery. Follow for 4 weeks Readouts: safety and biomarker assessments. Includes rate of AKI, duration, and severity 1. Only one Phase 1a study needed for both REVTx-100 and REVTx-300

------

![Slide 24](revb-ex99_1s24.jpg)

REVTx-200 Intranasal Adjunct for Improved Intramuscular (IM) Vaccination

------

![Slide 25](revb-ex99_1s25.jpg)

REVTx-200 Program Highlights - Traditional IM Immunization Alone: Increased systemic antibodies (IgG) Systemic protection Weak mucosal antibodies (IgA) Poor mucosal protection Transmission still active IM Immunization + REVTx-200: Increased systemic antibodies (IgG) Systemic protection Improved mucosal antibodies (IgA + IgM) Robust mucosal protection Transmission blunted/blocked Scientific Rationale Potential Market1 Next Steps Nonclinical POC (PEITHO) study readout Conduct additional non-clinical study to optimize dosing regimen REVTx-200 may have potential utility with multiple vaccines Secure strategic licensing and/or partnering opportunities for Phase 2 studies and commercialization 1. Markets and Markets, Research and Markets Clinical biomarker data supports proposed mechanism of action

------

![Slide 26](revb-ex99_1s26.jpg)

Financial Overview

------

![Slide 27](revb-ex99_1s27.jpg)

Beneficial holders Percent George Tidmarsh, M.D., Ph.D. (Chairman) 8.9% All other management 6.7% Total management 15.6% 5% or Greater George Tidmarsh, M.D., Ph.D. (Chairman) 8.9% AXA IM Prime Impact Fund 8.3% Cap Table Shares Common Stock 23,536,070 Public Warrants (REVBW) 10,511,597 Warrants1 12,031,444 Roll-over RSU's 257,047 Options granted2 352,313 Equity Pool (available for grant) 942,108 Fully Diluted 47,630,579 Financial Overview Includes (i) 8,333,334 Private Warrants w/exercise of $0.60, (ii) 165,976 Roll-over Warrants w/exercise of $2.68, (iii) 2,586,667 Common Stock Warrants w/exercise of $3.29, (iv) 362,134 Placement Agent Warrants w/exercise of $3.29, and 583,333 Placement Agent Warrants w/exercise of $0.75. Includes 156,492 options granted on 2/25/2022 w/exercise of $1.40 and 195,821 options granted on 7/29/2022 w/exercise of $0.563

------

![Slide 28](revb-ex99_1s28.jpg)

For more information please visit www.revbiosciences.com Thank you!